Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis

被引:0
|
作者
Koroma, Josephine Amie [1 ]
Elduma, Adel Hussein [2 ,3 ]
Sesay, Umaru [2 ]
Gebru, Gebrekrstos Negash [2 ,3 ]
机构
[1] Minist Hlth, Natl Leprosy & TB Control Program, Freetown, Sierra Leone
[2] Sierra Leone Field Epidemiol Training Program, EOC Bldg,Wilkinson Rd, Freetown, Sierra Leone
[3] African Field Epidemiol Network AFENET, EOC Bldg, Wilkinson Rd, Freetown, Sierra Leone
关键词
Multidrug-resistant tuberculosis; Unfavorable treatment outcomes; Sierra Leone; TB;
D O I
10.1186/s12879-024-09370-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Globally, multidrug-resistant tuberculosis (MDR-TB) is a major public health problem. The tuberculosis rate in Sierra Leone is 298 per 100,000 people, and Sierra Leone is considered a country with a high burden of tuberculosis. In Sierra Leone, there are few studies on the outcomes of MDR-TB treatment, especially those exacerbated by COVID-19. We identified factors associated with unfavorable treatment outcomes among people with MDR-TB in Sierra Leone.Methods We conducted a cross-sectional study to analyze hospital-based MDR-TB data from 2017 to 2021. Demographic, clinical, and treatment outcome data were extracted from the main MDR-TB referral hospital database. We defined unfavorable outcomes as patients who died, were lost to follow-up, or defaulted. We calculated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) to identify predictors of the outcomes of MDR-TB treatment.Results Between 2017 and 2021, 628 people with MDR-TB were reported at Lakka Hospital; 441 (71%) were male, with a median age of 25 years (interquartile ranges: 17-34). Clinically, 21% of the 628 MDR-TB patients were HIV positive, and 413 were underweight (66%). 70% (440) of MDR-TB patients received tuberculosis treatment. The majority of patients, 457 (73%), were treated with a short treatment regimen, and 126 (20%) experienced unfavorable outcomes. Age 45 years or younger (aOR = 5.08; CI:1.87-13.82), 21-45 years (aOR = 2.22; CI:140-3.54), tuberculosis retreatment (aOR = 3.23; CI:1.82-5.73), age group, HIV status (aOR = 2.16; CI:1.33-3.53), and malnourishment status (aOR = 1.79; CI:1.12-2.86) were significantly associated with unfavorable treatment outcomes for DR-TB patients.Conclusion This analysis revealed a high proportion of unfavorable treatment outcomes among MDR-TB patients in Sierra Leone. Malnourishment, TB retreatment, HIV coinfection, and age 45 years or younger were associated with unfavorable outcomes of MDR-TB treatment. Increasing patients' awareness, mainly among young people, heightens treatment adherence and HIV monitoring by measuring the amount of HIV in patient blood, which can reduce adverse treatment outcomes in Sierra Leone and other sub-Saharan African countries.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt
    Gadallah, Mohsen A.
    Mokhtar, Alaa
    Rady, Mervat
    El-Moghazy, Essam
    Fawzy, Magdy
    Kandil, Sahar Khalil
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2016, 115 (11) : 997 - 1003
  • [2] Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
    Desissa, Fanta
    Workineh, Tilaye
    Beyene, Takele
    BMC PUBLIC HEALTH, 2018, 18
  • [3] Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
    Fanta Desissa
    Tilaye Workineh
    Takele Beyene
    BMC Public Health, 18
  • [4] Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients
    Brode, Sarah K.
    Varadi, Robert
    McNamee, Jane
    Malek, Nina
    Stewart, Sharon
    Jamieson, Frances B.
    Avendano, Monica
    CANADIAN RESPIRATORY JOURNAL, 2015, 22 (02) : 97 - 102
  • [5] Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Southwestern Oromia, Ethiopia: ten-year retrospective analysis
    Bonsa, Zegeye
    Tadesse, Mulualem
    Bekele, Eba
    Abeba, Gari
    Solomon, Endashaw
    Husen, Mohammed
    Balay, Getu
    Kebede, Wakjira
    Abebe, Gemeda
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [6] Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study
    Zhang, Xiulei
    Yin, Jia
    Li, Haitao
    Li, Shuguang
    Walley, John
    Zou, Guanyang
    Zhang, Zhitong
    Wei, Xiaolin
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 (11) : 1431 - 1437
  • [7] Outcome and treatment among patients with multidrug-resistant tuberculosis
    Ramirez Lapausa, Marta
    Pascual Pareja, Jose Francisco
    Amer Perez, Mariam
    Vidal Perez, Jose Luis
    Noguerado Asensio, Arturo
    MEDICINA CLINICA, 2012, 138 (15): : 643 - 649
  • [8] Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen
    Babalik, Aylin
    Balikci, Ahmet
    Turkar, Ayla
    Teke, Nazli Huma
    Demir, Fatma Kubra
    Yavuz, Simge
    Koc, Emine Nur
    Gunduz, Senem
    Ergec, Buesra
    Alagoz, Hasan Can
    Sarioglu, Eren
    Kilicaslan, Zeki
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2024, 13 (03) : 265 - 274
  • [9] Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study
    Wang, Yun
    Chen, Huijuan
    Huang, Zhongfeng
    McNeil, Edward B.
    Lu, Xiaolong
    Chongsuvivatwong, Virasakdi
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 1641 - 1653
  • [10] Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis
    Shin, SY
    Furin, J
    Alcántara, F
    Hyson, A
    Joseph, K
    Sánchez, E
    Rich, M
    CHEST, 2004, 125 (03) : 974 - 980